The I-TECH Randomized Clinical Trial February 18, 2022 Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et alAnilawati Mat Jelani, MMed5; Wen Hao Tan, MMed6; Hong Bee Ker, MRCP1; Ting Soo Chow, MRCP7; Masliza Zaid, MMed8; Wee Kooi Cheah, MRCP6; Han Hua Lim, MRCP9; Khairil Erwan Khalid, MRCP10; Joo Thye Cheng, MRCP2; Hazfadzila Mohd Unit, MRCP11; Noralfazita An, MMed12; Azraai Bahari Nasruddin, MRCP13; Lee Lee Low, MRCP14; Song Weng Ryan Khoo, MRCP15; Jia Hui Loh, MRCP16; Nor Zaila Zaidan, MMed17; Suhaila Ab Wahab, MMed18; Li Herng Song, MD19; Hui Moon Koh, MClinPharm20; Teck Long King, BPharm21; Nai Ming Lai, MRCPCH22; Suresh Kumar Chidambaram, MRCP4; Kalaiarasu M. Peariasamy, MSc23; for the I-TECH Study Group Article Information Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is […]